PHOTO ESSAY: A Texas town's residents stay inside — even when they need medical care
As President Donald Trump intensifies deportation activity around the country, some immigrants — including many who have lived in Texas's southern tip for decades — are unwilling to leave their homes, even for necessary medical care.
'He waited and waited because he felt the pain but was too scared to go to the hospital.'
— 82-year-old Maria Isabel de Perez said of her son, whose appendix exploded earlier this year.
It feels like we're living in a combat area. Even people like me who have status, I don't want to go out either, we're scared. They're looking for any excuse. If they see you have brown skin or you're Latino, they'll take you.'
— Maria Gomez, a community health worker for Holy Family Services, Inc. said in Spanish, through an interpreter.
People here are among the most medically needy in the country.
Nearly half the population is
obese
. Women are more likely to be diagnosed with
cervical cancer
and elderly people are
more likely to develop dementia
. Bladder cancers can be
more aggressive
. One out of every four people live with
diabetes
.
As much as a
third of the population
here doesn't have health insurance to cover those ailments. And a quarter of people live in poverty, more than double the national average.
Now, many in this region are on a path to develop worse health outcomes as they skip doctors appointments out of fear, said Dr. Stanley Fisch, a pediatrician who helped open Driscoll Children's Hospital in the region last year.
White House officials have directed federal agents to leave no location, including hospitals and churches, unchecked in their drive to
remove 1 million immigrants by year's end
. Those agents are even combing through one of the federal government's largest medical record databases to search for immigrants who may be in the United States illegally.
Federal agents' raids began reaching deeper into everyday life across the Rio Grande Valley in June, just as the area's 1.4 million residents began their summer ritual of enduring the suffocating heat.
This working-class stretch of Texas solidly backed Trump in the 2024 election, despite campaign promises to ruthlessly pursue mass deportations. People here, who once moved regularly from the U.S. to Mexico to visit relatives or get cheap dental care, say they didn't realize his deportation campaign would focus on their neighbors.
It feels like we're living in a combat area. Even people like me who have status, I don't want to go out either, we're scared. They're looking for any excuse. If they see you have brown skin or you're Latino, they'll take you.'
— Maria Gomez, a community health worker for Holy Family Services, Inc. said in Spanish, through an interpreter.
'Every day, I pray that the president will have a change of heart.'
— Maria, a mother who is married to an American in south Texas.
'What did we do to them?'
— Ofelia, a 73-year-old grandmother in Hidalgo County who is the sole caretaker of several grandchildren.
This is a documentary photo story curated by AP photo editors.
Text from the APNews story,
As Trump's raids ramp up, a Texas region's residents stay inside — even when they need medical care
, by Amanda Seitz and Jacquelyn Martin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Geneoscopy's New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
ST. LOUIS--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The newly approved collection kit no longer requires patients to separate their sample into multiple containers. This improves ease of use and reduces barriers to at-home screening, 1 while maintaining clinical performance. 'We've taken a critical step toward improving the at-home colorectal cancer screening experience by removing one of the most burdensome aspects for patients—the scraping of stool,' said Dr. Erica Barnell, Chief Medical & Science Officer of Geneoscopy. 'The new collection kit simplifies the process for collecting a patient's stool sample. By eliminating the most confusing and undesirable step, we believe ColoSense will drive higher adherence and better outcomes.' ColoSense is indicated for individuals aged 45 and older who are at average risk for CRC. It uses advanced RNA technology to detect biomarkers associated with CRC and advanced adenomas (AA)—precancerous growths that can develop into cancer if left untreated. As the only FDA-approved RNA-based test for CRC screening, ColoSense demonstrated 93% sensitivity for CRC and 45% sensitivity for AA in average-risk individuals. Among average-risk individuals aged 45 to 49, where CRC incidence is on the rise, the test demonstrated 100% sensitivity for CRC and 44% sensitivity for AA.* Despite the availability of multiple screening options, an estimated 44 million people aged 45-75 remain unscreened for CRC. 2 To help address a common barrier to stool-based screening, the updated ColoSense collection kit removes the need to scrape the sample. This improvement is expected to increase patient compliance, lower the rate of collection errors, and reduce the frequency of invalid samples. This ease of use can translate into fewer missed screenings and a greater overall impact on population health. 'To exceed 80% compliance for colorectal cancer screening, the patient experience for stool-based screening must be improved,' said Andrew Barnell, Chief Executive Officer of Geneoscopy. 'The new ColoSense test does that, offering patients everything they like about at-home, high-sensitivity screening, but now, with an easier collection process.' ColoSense is included in National Comprehensive Cancer Network (NCCN) guidelines, based on an evaluation of the strength of its clinical evidence and the robust science behind the technology. The test will be available through Geneoscopy's strategic collaboration with Labcorp, expanding access for providers and patients across the United States. ColoSense represents a significant advancement in noninvasive stool testing options, reinforcing the importance of accessible tools that help reach individuals who are less likely to undergo colonoscopy. About ColoSense ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA). For more information, visit About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn. References Luque JS, Wallace K, Blankenship BF, et al. Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think. J Community Health. 2018;43(6):1085-1092. doi:10.1007/s10900-018-0525-x Hyams T, Mueller N, Curbow B, et al. Screening for colorectal cancer in people ages 45–49: research gaps, challenges and future directions for research and practice, Transl. Behav. Med, Volume 12, Issue 2, Feb 2022, Pages 198–202. *ColoSense identified 5/5 colorectal cancers and 37/84 advanced adenomas.
Newsweek
26 minutes ago
- Newsweek
Elektra Health Wants to Demystify Menopause, Says CEO Jannine Versi
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Women's bodies are often a mystery to even women themselves. Part of that mystery stems from the invisibility of women's health topics in the American health care industry. But this was never the case for Jannine Versi. She grew up being the eldest of three girls in a predominantly female household, so puberty, overactive bladder and menopause were simply everyday dinner table conversations. Versi carried those discussions into the creation of her own venture, Elektra Health. Co-founded in 2019 by Versi and Alessandra Henderson, the company serves as a digital health support platform for women navigating menopause. Versi's career has been multifaceted as she worked in both the public and private sectors, progressing from Wall Street to microfinance in India, from Google to Insomnia Cookies, and eventually to tech-focused health care companies Cityblock Health and Valera Health. Jannine Versi is the co-founder and CEO of Elektra Health, a women's health company. Jannine Versi is the co-founder and CEO of Elektra Health, a women's health company. Newsweek Illustration/Canva Throughout the majority of her early experiences, Versi interacted with powerful women in each of their respective spaces. She had the opportunity to collaborate with women like Google's Chief Marketing Officer Lorraine Twohill, former Secretary of Commerce Penny Pritzker and Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health. As a result, she came to believe that women in leadership positions existed everywhere. However, upon further research, she realized that not everyone grew up in the same open environment that she did, and this led her back to the dinner table conversations in her household. "Women are the engine of the health care system, yet their perspectives are often missing from the rooms where decisions get made," Versi told Newsweek. Despite being at the center of some of the most prevalent issues in the health care industry, women have historically been underrepresented in medical research. According to a study from the American Journal of Obstetrics and Gynecology, 4.5 million women in the U.S. experience at least one gynecologic health problem each year, and the majority are related to menstrual health. Health care payers and systems are still figuring out how to prioritize women's health, but this issue extends into a matter of public health, leading to increased disease risk, untreated symptoms and missed diagnoses. For instance, according to a 2022 report published in the American Heart Journal Plus: Cardiology Research and Practice, women have been consistently underrepresented in cardiovascular clinical trials, and cardiovascular disease is now the leading cause of death in women. Women are much less likely than men to be considered in clinical and preclinical cardiovascular research, which leads to a lack of awareness regarding how they display symptoms differently from men and how they react to treatments. The turning point for Versi was in the late 2010s. While working at Cityblock Health, she witnessed firsthand how access to social support systems could improve outcomes for Medicaid and Medicare patients. During this time, she was a member of the founding team that initiated a value-based care model, blending advanced primary care with access to social supports. Simultaneously, she was observing the pioneering work of Maven Clinic, a virtual clinic for women's and family health, and noticed that while it focused on fertility and pregnancy, it neglected to address the mid-life and later stages of women's health. "Midlife women are often dismissed, misdiagnosed or completely overlooked in our health care system—despite being at the center of their families, communities, and workplaces," Versi said. Elektra Health was founded to bridge the glaring gap in women's health care, as well as the general lack of access. Its goal is to make women feel seen and heard throughout each stage of their lives. The company offers virtual clinical care services with board-certified clinicians, education and peer support, all of which are covered by insurance. The company's website features multiple educational articles on stages including perimenopause and menopause. It also publishes a newsletter featuring up-to-date science, stories and recommendations for the modern woman seeking to learn more about maintaining her health. Additionally, various symptoms of menopause are listed, along with tips from clinicians on how to manage each one, the science behind why they occur and recommended medications. Elektra Health stands out due to its definition of success. It doesn't measure its achievements in terms of numbers or revenue but instead focuses on psychosocial impact on women. The company's goal is to understand whether women are feeling more informed, better supported and equipped to deal with changes in their health as a result of their services. "We want women to live long, as they increasingly are, but in great health," Versi said. She mentioned that Elektra Health often considers the question, "How many women are accessing care who weren't before?" As a team that primarily identifies as women, the female-founded company works to ensure it approaches the concerns of fellow women with as much urgency and empathy as possible as they experience these confusing and challenging stages of their lives. "It hasn't been easy," Versi said. "Bootstrapping a menopause company during the early days of a pandemic was brutal. We're solving invisibility and lack of access." Elektra Health is also the first menopause company to ever successfully partner up with a health plan, Mass General Brigham Health Plan, and the first and only midlife women's health company serving Medicare and Medicaid patients through its payer partnerships. Versi and her team also work with a few partner organizations that are focusing on prioritizing research on women's health. The University of Pittsburgh Medical Center (UPMC) and EmblemHealth are two examples, both led by women, of organizations actively working to bridge the gap in knowledge and access regarding women's health. Versi believes that we need more women leading the charge in health care and playing an active role in the decisions that affect their health in real time. Nevertheless, this cannot be achieved without robust systems being put in place to retain their positions in leadership and promote them to carry forward bigger and better initiatives. Creating synergy between women's health research and the resulting decisions that care providers make will help women finally feel less invisible and alone in their struggles, Versi said. "I have heard for a long time from various payers and systems that they are 'still figuring out' their women's health strategy," said Versi. "I suspect some will regret not moving more swiftly because women are increasingly and rightly expecting better from their providers and insurers. That kind of leadership sets a new standard—and hopefully, it's just the beginning." Versi will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions. For more information on the event, please visit the Women's Global Impact homepage.
Business Wire
an hour ago
- Business Wire
FUJIFILM Sonosite Redefines Superficial Imaging with the New UHF46-20 Transducer, the World's First 46MHz Ultra High Frequency Transducer for Point-of-Care Ultrasound
BOTHELL, Wash.--(BUSINESS WIRE)-- FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound (POCUS) solutions, today announced a revolutionary advancement in point-of-care ultrasound imaging with the introduction of their UHF46-20 Transducer. This groundbreaking transducer is the first and only 46MHz Ultra-High Frequency (UHF) transducer available today in the point-of-care ultrasound market 1, setting a new standard for superficial image clarity and detail. With a minimum scan depth of 4mm, the UHF46-20 Transducer will enable clinicians to clearly visualize the first one to two centimeters beneath the skin and identify structures smaller than 1mm, such as superficial nerves and vessels, with high-quality resolution. Built upon the advanced Ultra High Frequency technology from FUJIFILM VisualSonics, and available exclusively on the FUJIFILM Sonosite LX POCUS system, this innovative technology provides the best superficial imaging 2,3,4 available on any point-of-care ultrasound system 1. 'At FUJIFILM Sonosite, we are driven by a commitment to help solve real-world challenges clinicians and providers face. The UHF46-20 transducer, when paired with the Sonosite LX system, enables the largest frequency range of any point-of-care ultrasound system on the market today - addressing a longstanding challenge that current clinical ultrasound systems have been unable to overcome,' said Richard Fabian, president and chief executive officer of FUJIFILM Sonosite, Inc. 'We're proud to bring to market the UHF46-20 Transducer as the first and only 46MHz UHF transducer in POCUS to provide clinicians with an unparalleled tool that may help them enhance diagnostic confidence and procedural accuracy.' The combination of the new transducer and the Sonosite LX offers clinicians a versatile solution for a wide spectrum of imaging needs, spanning from deep abdominal scans to ultra-high resolution superficial assessments. The UHF46-20 Transducer holds promise for improving outcomes across a range of sensitive applications including Neonatal Intensive Care Unit (NICU) and Rheumatology. In the NICU, its superior resolution may help clinicians see superficial submillimeter anatomy that conventional ultrasound may not capture. 6,11 The use of UHF ultrasound may aid clinicians in improving procedural quality by allowing for better visualization of tiny anatomy that may help to improve first attempt success rates. 4,8,9,10 In Rheumatology, UHF's advanced superficial imaging may aid in the visualization of subclinical synovitis, erosions, crystal deposits, and inflammation, all of which are beneficial in the early diagnosis and intervention of chronic conditions. 2,3,7 To learn more about the UHF46-20 Transducer, visit the product page at About FUJIFILM FUJIFILM Sonosite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit: References Internal Fujifilm research as of April 2025. Albano, D., Aringhieri, G., Messina, C., De Flaviis, L., & Sconfienza, L. M. (2020). High-Frequency and Ultra-High Frequency Ultrasound: Musculoskeletal Imaging up to 70 MHz. Seminars in musculoskeletal radiology, 24 (2), 125–134. Russo, A.; Reginelli, A.; Lacasella, G.V.; Grassi, E.; Karaboue, M.A.A.; Quarto, T.; Busetto, G.M.; Aliprandi, A.; Grassi, R.; Berritto, D. Clinical Application of Ultra-HighFrequency Ultrasound. J. Pers. Med. 2022, 12, 1733. 10.3390/jpm12101733 Ait Ichou, J., Gauvin, S., & Faingold, R. (2021). Ultra-high-frequency ultrasound of superficial and musculoskeletal structures in the pediatric population. Pediatric radiology, 51 (9), 1748–1757. Hayashi, A., Giacalone, G., Yamamoto, T., Belva, F., Visconti, G., Hayashi, N., Handa, M., Yoshimatsu, H., & Salgarello, M. (2019). Ultra High-frequency Ultrasonographic Imaging with 70 MHz Scanner for Visualization of the Lymphatic Vessels. Plastic and reconstructive surgery. Global open, 7 (1), e2086. Latham, G. J., Veneracion, M. L., Joffe, D. C., Bosenberg, A. T., Flack, S. H., & Low, D. K. (2013). High-frequency micro-ultrasound for vascular access in young children--a feasibility study by the High-frequency UltraSound in Kids studY (HUSKY) group. Paediatric anaesthesia, 23 (6), 529–535. Viviano, S. L., Chandler, L. K., & Keith, J. D. (2018). Ultrahigh Frequency Ultrasound Imaging of the Hand: A New Diagnostic Tool for Hand Surgery. Hand (New York, N.Y.), 13(6), 720–725. Jacobsen RB, Hebelka H, Gatzinsky V, Elfvin A, Dangardt F. Ultra-high-frequency ultrasound (48–70 MHz) is a promising tool for improved gastrointestinal diagnostics in infants. Acta Paediatr. 2024; 113: 2304–2311. Brusciano, V., & Lecce, M. (2024). Advantages of the use of ultrasound in newborn vascular access: a systematic review. Journal of ultrasound, 27 (2), 203–207. Currie M, Vashisht R, Elkin D, et al. Ultrasound Intravascular Access. [Updated 2024 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Salvia, G.; Zerbinati, N.; Manzo Margiotta, F.; Michelucci, A.; Granieri, G.; Fidanzi, C.; Morganti, R.; Romanelli, M.; Dini, V. Ultra-High-Frequency Ultrasound as an Innovative Imaging Evaluation of Hyaluronic Acid Filler in Nasolabial Folds. Diagnostics 2023, 13, 2761. diagnostics13172761 Hawez, T., Evertsson, M., Erlöv, T. et al. The use of ultra-high frequency ultrasound in identifying aganglionosis in Hirschsprung's disease. Sci Rep 15, 15124 (2025).
